Unlock instant, AI-driven research and patent intelligence for your innovation.

Synthesis of novel xylose free occidiofungin analogues and methods of using them

a technology of xylose and ocidiofungin, which is applied in the field of synthesis of novel xylose free ocidiofungin analogues, can solve the problems of infection and mortality in all hospitalized patients, invasive fungal infections are still a major cause of morbidity and mortality in transplant patients, and achieve superior pharmacological properties and reduce inflammation and toxicity

Pending Publication Date: 2021-06-10
SANO CHEM +1
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

This patent describes methods for creating new compounds that can be used to treat fungal infections. These compounds have reduced inflammation and toxicity compared to natural compounds found in mushrooms. This invention also provides methods for modifying these compounds to create even more new treatments. Overall, this patent provides a way to develop new and effective treatments for fungal infections.

Problems solved by technology

There is no established treatment method for VVC, which has led to the development of several ineffective treatment methods.
Candida species are an important cause of infection and mortality in all hospitalized patients.
Despite current antifungal drugs, invasive fungal infections are still a major cause of morbidity and mortality in transplant patients.
The prevalence of echinocandin and azole-resistant fungal pathogens and the limited spectrum of activity of those compounds is one major issue contributing to the need for a new class of antifungals.
Additionally, current antifungal treatments lead to abnormal liver and kidney function tests and have limitations with respect to their spectrum of activity and toxicities.
These limitations and toxicity problems have created an urgent need to identify antifungal compounds that have new fungal cell targets.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Synthesis of novel xylose free occidiofungin analogues and methods of using them
  • Synthesis of novel xylose free occidiofungin analogues and methods of using them
  • Synthesis of novel xylose free occidiofungin analogues and methods of using them

Examples

Experimental program
Comparison scheme
Effect test

example 1

of Semisynthetic Analogues of Occidiofungin

[0106]Occidiofungin was produced and purified as described by Lu et al. and Emrick et al. Chemicals were purchased from Sigma unless otherwise indicated. Wild-type MS14 strain and xylose transferase mutant strain used were obtained from glycerol stocks and cultured on Yeast Peptone Dextrose (YPD) agar plate or broth at 35° C. Occidiofungin was produced from these cultures and used to produce OF-Δxyl analogues as described herein.

[0107]Cleavage of diols on carbons 5 and 6 of the novel amino acid yields an aldehyde containing OF-Δxyl analogue. Sodium periodate breaks apart vicinal diols to form an aldehyde containing analogue of OF-Δxyl (FIGS. 3A-3B). Occidiofungin was dissolved in 50% ACN with 0.1% TFA at a concentration of 1 mg / mL. Sodium periodate was dissolved in ddH2O at a concentration of 1 mg / mL. Equal volume of the two solutions were mixed in a centrifuge tube and incubated at various temperatures from 30-70° C. for 30 min. The reacti...

example 2

nhibitory Concentration (Mic) of the OF-Δxyl Analogues

[0113]Minimum inhibitory concentration (MIC) susceptibility testing was performed following a modified version, as previously reported, of the CLSI M27-A3 methods for the susceptibility testing of yeasts. Incubation temperature was 35° C. and the inoculum size was 0.5-2.5×103 colony-forming units (CFU) / mL for yeasts. MICs were performed to determine the bioactivity of each new OF-Δxyl analogue (Table 3). The minimal inhibitory concentration (MIC) is the lowest concentration of compound that inhibits the visible growth of the yeast after 24 hours of incubation and the assays were performed in duplicate. The aldehyde containing OF-Δxyl analogues with the addition of an undecylamine, dodecylamine, or DL-dihydrosphingosine did not demonstrate any inhibitory activity against C. albicans at the concentration tested. However, the addition of DL-dihydrosphingosine to the aldehyde containing OF-Δxyl analogue exhibited a low micromolar inh...

example 3

l Examples OF-Δxyl Analogues

[0115]The aldehyde containing OF-Δxyl analogue can be used to create new analogues of occidiofungin besides the amine containing OF-Δxyl analogues described above. Synthesis of triazoles can be readily accomplished by addition of various aryl azide in the presence of Cu(ACAC) as a catalyst. This allows for the introduction of various aryl groups and conversion of the aldehyde into a triazole.

[0116]Synthesis of hydrazones: The aldehyde occidiofungin (1) can be treated with a variety of phenyl hydrazines such as i) 2-nitrophenyl hydrazine, 4-nitrophenyl hydrazine or 2,4-dinitrophenyl hydrazine (2,4 DNPH) to produce novel hydrazones. The nitro groups on these hydrazones can be readily reduced using a variety of reducing agents such as NaBH4 / Pd, Pd / H2 and stannous chloride to produce the corresponding amines. The resulting aromatic amines can be subjected to reductive amination with a variety of aliphatic or aromatic aldehydes, such as acetaldehyde, linear ch...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The subject invention pertains to methods for producing novel occidiofungin analogues lacking xylose (OF-Δxyl analogue). OF-Δxyl analogues can contain aldehyde, amine, triazole, or hydrazones. The aldehyde, amine, triazole or hydrazone containing analogues of OF-Δxyl can be further modified by substitution with additional functional groups. Various OF-Δxyl analogues described herein have reduced inflammation and toxicity and superior pharmacological properties compared to the natural occidiofungins. Accordingly, certain embodiments of the invention provide methods of treating or preventing fungal infections by administering to the subjects in need thereof the OF-Δxyl analogues described herein.

Description

CROSS-REFERENCE TO RELATED APPLICATION[0001]This application claims the benefit of U.S. Provisional Application Ser. No. 62 / 653,253, filed Apr. 5, 2018, the disclosure of which is hereby incorporated by reference in its entirety, including all figures, tables and amino acid or nucleic acid sequences.[0002]This invention was made with government support under 1R41A1122441-01A1 awarded by the NIH-NIAID. The government has certain rights in the invention.[0003]The Sequence Listing for this application is labeled “Seq-List.txt” which was created on Apr. 5, 2019 and is 1 KB. The entire content of the sequence listing is incorporated herein by reference in its entirety.BACKGROUND OF THE INVENTION[0004]Fungal infections caused by pathogens that are resistant to commonly used classes of antifungals are becoming increasingly prevalent. A CDC report described the spread of multi-drug resistant Candida auris causing systemic infections in hospitalized patients. Furthermore, other species such ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/395A61K38/12A61P43/00
CPCA61K31/395A61P43/00A61K38/12A61P31/10A61P15/02C07K7/56C07K7/64C07K7/60
Inventor SMITH, JAMES L.GENG, MENGXINRAVICHANDRAN, AKSHAYAORUGUNTY, RAVI
Owner SANO CHEM